Cantor Fitzgerald raised its price target for Eli Lilly and Company to $1,230 per share following the company's first-quarter earnings call [1].
The adjustment reflects growing investor confidence in the pharmaceutical giant's ability to scale its weight-loss and diabetes portfolio. As competition in the GLP-1 market intensifies, Eli Lilly's financial performance serves as a benchmark for the sector's growth potential.
The new target is an increase from the previous valuation of $1,200 per share [1]. This move comes after Eli Lilly reported strong results for the first quarter of fiscal year 2025, which included a 45% year-over-year increase in revenue [2].
The company's growth was primarily driven by the performance of its drugs Mounjaro and Zepbound [2]. These medications have seen significant demand as the market for obesity and diabetes treatments expands globally.
Financial reports for the quarter showed earnings per share of $3.34 [2]. Additionally, the company recorded in-process research and development charges of $1.72 per share [2].
Eli Lilly is listed on the New York Stock Exchange [3]. The company's ability to maintain high growth rates while managing the costs of research and development remains a central focus for analysts tracking the stock.
“Cantor Fitzgerald raised its price target for Eli Lilly and Company to $1,230 per share”
The price target increase suggests that analysts believe Eli Lilly has not yet reached its peak valuation despite the high price of its shares. By linking the target lift to the success of Mounjaro and Zepbound, the market is signaling that the commercial viability of GLP-1 agonists is the primary driver of the company's enterprise value, outweighing the impact of significant R&D charges.
